Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

NCT00072150 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00072150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00072150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2003
Completion date
Not reported
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic transitional cell cancer of the renal pelvis and ureter, recurrent bladder cancer, recurrent transitional cell cancer of the renal pelvis and ureter, recurrent urethral cancer, stage iii bladder cancer, stage iii urethral cancer, stage iv bladder cancer, stage iv urethral cancer, transitional cell carcinoma of the bladder, ureter cancer